BioCryst Pharmaceuticals, Inc. (BMV:BCRX)

Market Cap	38.22B
Revenue (ttm)	10.29B
Net Income (ttm)	-1.09B
Shares Out	n/a
EPS (ttm)	-5.30
PE Ratio	n/a
Forward PE	35.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,900
Average Volume	555
Open	197.00
Previous Close	201.00
Day's Range	197.00 - 197.50
52-Week Range	138.00 - 215.00
Beta	n/a
RSI	49.91
Earnings Date	Aug 4, 2025

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 580
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BCRX

Financial Performance

In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.

Financial numbers in USD